LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.74 USD
Market Cap: 45.8m USD

LAVA Therapeutics NV
Cash from Investing Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

LAVA Therapeutics NV
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Cash from Investing Activities
$12.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Cash from Investing Activities
$17m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Cash from Investing Activities
-€3.3m
CAGR 3-Years
-54%
CAGR 5-Years
-26%
CAGR 10-Years
-6%
Uniqure NV
NASDAQ:QURE
Cash from Investing Activities
$93.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Cash from Investing Activities
-$717.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Cash from Investing Activities
-$93.5m
CAGR 3-Years
-89%
CAGR 5-Years
-96%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
45.8m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.52 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Cash from Investing Activities?
Cash from Investing Activities
12.5m USD

Based on the financial report for Dec 31, 2024, LAVA Therapeutics NV's Cash from Investing Activities amounts to 12.5m USD.

Back to Top